[28] Our clinical data suggest that PKM2 has a potential role in predicting early recurrence in patients with HCC, particularly those without known risk factors (63.6%), implying that PKM2 may be a relevant tumor marker and therapeutic target for HCC treatment. This evidence concerns the gene PKM and hepatocellular carcinoma.